Cognition Therapeutics announces positive results from trial of oral treatment for mild-to-moderate Alzheimer’s disease
The Purchase, N.Y.-based company found patients treated with its experimental pill CT1812 for six months showed a consistent trend in cognitive improvement across all measures and cognitive scales.
